Authors:
Gelmann, EP
Chia, D
Pinsky, PF
Andriole, GL
Crawford, ED
Reding, D
Hayes, RB
Kramer, BS
Woodrum, DL
Gohagan, JK
Levin, DL
Citation: Ep. Gelmann et al., Relationship of demographic and clinical factors to free and total prostate-specific antigen, UROLOGY, 58(4), 2001, pp. 561-566
Authors:
Partin, AW
Catalona, WJ
Finlay, JA
Darte, C
Tindall, DJ
Young, CYF
Klee, GG
Chan, DW
Rittenhouse, HG
Wolfert, RL
Woodrum, DL
Citation: Aw. Partin et al., Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis, UROLOGY, 54(5), 1999, pp. 839-845
Authors:
Catalona, WJ
Partin, AW
Finlay, JA
Chan, DW
Rittenhouse, HG
Wolfert, RL
Woodrum, DL
Citation: Wj. Catalona et al., Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model, UROLOGY, 54(2), 1999, pp. 220-224
Authors:
Chan, DW
Kelley, CA
Ratliff, TL
D'Agostino, D
Ritchey, J
Lamb, DJ
Beck, J
Lott, N
Wener, MH
Daum, P
Henkin, RE
Kaske, DN
Golightly, DW
McBride, J
Layco, G
Ota, MK
Tanasijevic, MJ
Grudzien, C
Woodrum, DL
Bray, KR
Southwick, PC
Gasior, GH
Loveland, KG
Citation: Dw. Chan et al., Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine theclinical utility of percentage of free prostate-specific antigen, CLIN CHEM, 45(10), 1999, pp. 1863-1865